Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
UroGen Pharma Ltd (NASDAQ: URGN) closed the day trading at $22.98 down -5.35% from the previous closing price of $24.28. In other words, the price has decreased by -$5.35 from its previous closing price. On the day, 0.82 million shares were traded. URGN stock price reached its highest trading level at $24.65 during the session, while it also had its lowest trading level at $22.51.
Ratios:
For a better understanding of URGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.79 and its Current Ratio is at 3.99.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On June 16, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when Schoenberg Mark sold 10,000 shares for $25.00 per share. The transaction valued at 250,000 led to the insider holds 139,025 shares of the business.
Schoenberg Mark bought 10,000 shares of URGN for $250,005 on Nov 19 ’25. On Oct 08 ’25, another insider, Degnan Chris, who serves as the Chief Financial Officer of the company, sold 2,203 shares for $16.85 each. As a result, the insider received 37,121 and left with 2,280 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 1075668352 and an Enterprise Value of 1078575360. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.14. Its current Enterprise Value per Revenue stands at 11.175 whereas that against EBITDA is -8.227.
Stock Price History:
The Beta on a monthly basis for URGN is 1.29, which has changed by 0.88824975 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $30.00, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 8.76%, while the 200-Day Moving Average is calculated to be 51.65%.
Shares Statistics:
Over the past 3-months, URGN traded about 1.18M shares per day on average, while over the past 10 days, URGN traded about 888030 shares per day. A total of 46.78M shares are outstanding, with a floating share count of 38.61M. Insiders hold about 17.50% of the company’s shares, while institutions hold 93.16% stake in the company. Shares short for URGN as of 1763078400 were 8976703 with a Short Ratio of 7.60, compared to 1760486400 on 11148494. Therefore, it implies a Short% of Shares Outstanding of 8976703 and a Short% of Float of 19.469998999999998.
Earnings Estimates
A detailed examination of UroGen Pharma Ltd (URGN) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.36 and low estimates of -$0.63.
Analysts are recommending an EPS of between -$2.64 and -$3.4 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$0.59, with 7.0 analysts recommending between $2.44 and -$1.7.
Revenue Estimates
8 analysts predict $41.45M in revenue for. The current quarter. It ranges from a high estimate of $51.57M to a low estimate of $32.86M. As of. The current estimate, UroGen Pharma Ltd’s year-ago sales were $24.57MFor the next quarter, 8 analysts are estimating revenue of $43.66M. There is a high estimate of $46.88M for the next quarter, whereas the lowest estimate is $40.1M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $123.52M, while the lowest revenue estimate was $104.81M, resulting in an average revenue estimate of $113.4M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $253.13M in the next fiscal year. The high estimate is $391.48M and the low estimate is $191.1M.
